17 SEARCH RESULTS FOR: FDA

NCCS Urges FDA to Finalize Graphic Health Warnings for Cigarette Packs and Advertisements

/in , , , , ,

NCCS joined with public health and medical organizations in a comment letter to the U.S. Food and Drug Administration (FDA) regarding the proposed rule to establish health warnings for cigarette packages and advertisements. The comment letter outlines the overwhelming evidence that shows color graphic health warnings on cigarette packages and ads substantially increases and promotes greater public understanding of the dangers of smoking, […]

Read more

NCCS Joins Cancer Leadership Council Recommendations to FDA Regarding the Biosimilar Action Plan

/in , , , , , ,

NCCS joined with other organizations of the Cancer Leadership Council (CLC) in commenting on the FDA Biosimilar Action Plan (BAP). The comment letter commended the FDA for the development of a plan that balances both innovation and competition. The letter stated that these products provide significant benefits to cancer patients, but that they also come at a significant expense to patients and the health care system. […]

Read more

NCCS Joins Cancer Leadership Council to Oppose Right to Try Legislation in the House

/in , , , , , , , , ,

The National Coalition for Cancer Survivorship joined with other organizations of the Cancer Leadership Council (CLC) in a letter to House leadership to oppose House consideration of the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act (S. 204).The legislation passed the House on May 22 and goes to the President […]

Read more

NCCS Joins Letter Expressing “Serious Reservations” About “Right to Try” Legislation

/in , , , , , ,

NCCS joined with colleagues in the Cancer Leadership Council to express serious reservations about proposed “right to try” legislation that will remove the Food and Drug Administration (FDA) from the approval process for patient access to an investigational therapy outside a clinical trial. NCCS does not believe that right to try legislation removing FDA from […]

Read more

NCCS Comments on the FDA’s PDUFA Proposed Commitment Letter

/in , , , , ,

NCCS submitted comments to the Food and Drug Administration (FDA) on the letter representing the agreement between FDA and regulated industry on goals for the re-authorization of the Prescription Drug User Fee Act (PDUFA VI). NCCS participated in the PDUFA stakeholder meetings held over the last year, and we support the role […]

Read more

NCCS Joins Letter to Reagan-Udall Foundation Regarding the Expanded Access Navigator Program

/in , , , ,

NCCS joined with patient advocacy organizations in the Cancer Leadership Council (CLC) in submitting comments to the Reagan-Udall Foundation regarding the Draft Project Proposal for the Expanded Access Navigator for Individual Patient Access. In our letter, we commend the revisions to guidance documents, FDA educational materials, and the FDA website related to expanded access and […]

Read more

A Voice for Cancer Survivors in the PDUFA Stakeholder Meetings

/in , , , , ,

In 1992, Congress passed the first Prescription Drug User Fee Act (PDUFA), a law that allows the Food and Drug Administration (FDA) to collect fees from drug companies that apply to the FDA for approval to market their drugs for specific medical conditions, e.g., a chemotherapy drug for ALK-positive lung cancer. All drugs that treat […]

Read more

NCCS Policy Comments: FDA’s Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs)

/in , , , , ,

NCCS submitted comments to the Food and Drug Administration (FDA) on the Draft Guidance: Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs).  We support the FDA’s efforts to develop a strong regulatory framework for LDTs and commend the agency for the open and transparent process it has pursued in developing the framework and receiving […]

Read more

NCCS Policy Comments: Recommending Cancer Survivorship as a Topic for FDA Patient-Focused Drug Development Meetings

/in , , , , ,

Last week, NCCS submitted comments to the U.S. Food and Drug Administration (FDA) regarding the series of patient-focused drug development meetings that have been convened and the list of disease topic meetings scheduled for 2016-2017. In 2013, FDA convened a patient-focused drug development meeting related to lung cancer and has plans to convene a breast […]

Read more

NCCS Offers Policy Comments: Strategies for Increasing Patient Participation in FDA Review Activities

/in , , , , , ,

The Food and Drug Administration Safety and Innovation Act (FDASIA) authorized a patient-focused drug development program, and in the years since enactment, the U.S. Food and Drug Administration (FDA) has implemented certain initiatives of the patient-focused program. In recent weeks, FDA has requested feedback regarding patient-focused activities to date and recommendations about future efforts and […]

Read more

Take Action

Link to: Survivorship Champions

Become a Survivorship Champion

Survivorship Champions is a program for all clinicians and researchers, both oncology and primary care, who are interested in improving survivorship care and primary care’s role in caring for cancer survivors.

Learn More and Join »
Link to: Cancer Policy and Advocacy Team (CPAT)

Join CPAT

The NCCS Cancer Policy & Advocacy Team (CPAT) is a program for survivors and caregivers to learn about pressing policy issues that affect quality cancer care in order to be engaged as advocates in public policy around the needs of cancer survivors.

Learn More and Join »
Link to: Survivor Stories

Share Your Story

NCCS represents the millions of Americans who share a common experience – living with, through and beyond a cancer diagnosis. By sharing your story of how you have been touched by cancer, you are supporting the national cancer survivorship movement.

Share Your Story »

STAY CONNECTED

Together we can improve cancer care for survivors! Sign up to be the first to know about cancer policy issues and ways to take action

  • This field is for validation purposes and should be left unchanged.

Charity Navigator Four-Star Rating

National Coalition for Cancer Survivorship
8455 Colesville Road  |  Suite 930 | Silver Spring, MD 20910
info@canceradvocacy.org | (877) NCCS-YES
Privacy Policy  |  Terms and Conditions

Copyright © 1995-2024 by the National Coalition for Cancer Survivorship
National Coalition for Cancer Survivorship, NCCS, Cancer Survival Toolbox, and related Logos are registered in the United States as trademarks of the National Coalition for Cancer Survivorship.